Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

詳細情報 詳細情報について

• CRID

  1362262945769019776

• DOI

  10.3389/fonc.2019.00132

• ISSN

  2234943X

• Web Site

  https://www.frontiersin.org/article/10.3389/fonc.2019.00132/full

• データソース種別

  • Crossref